US Stock Market Move | Eli Lilly (LLY.US) rises nearly 3% and reaches a AI large molecule research and development cooperation with Crystal Tai Technology in the field of dual antibodies.

On Wednesday, Eli Lilly (LLY.US) rose nearly 3% to $933.34. In terms of news, JC Biotech announced that its wholly-owned subsidiary Ailux has reached a strategic cooperation and platform authorization agreement with Eli Lilly, with a total value of up to $345 million, including tens of millions of dollars in upfront payments and near-term milestone payments. According to the agreement, Eli Lilly can nominate multiple target groups, and Ailux is responsible for designing and optimizing bispecific drug candidates. Ailux is eligible to receive tens of millions of dollars in upfront payments and near-term milestone payments, as well as future payments for research, registration, and commercialization milestones. In addition, Eli Lilly also has the right to use Ailux's artificial intelligence bispecific design platform.